ArticleBMC cardiovascular disorders2025
Early pathological changes of coronary microvasculation in heart failure with preserved ejection fraction.
Article in BMC cardiovascular disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Heart Failure with Reduced versus Preserved Ejection Fraction: Molecular Mechanisms, Immunologic Pathways, Current Therapies, and Future Directions.Archives of internal medicine research · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundThe majority of heart failure with preserved ejection fraction (HFpEF) patients present with coronary microvascular dysfunction (CMD). However, it is uncertain whether CMD is a primary factor in ventricular remodeling/diastolic dysfunction and HFpEF, or whether CMD is secondary to myocardial remodeling in HFpEF.
methodsEight-week-old male C57BL/6N mice were simultaneously administered with high-fat diet (HFD) and N(ω)-nitro-L-arginine methyl ester (L-NAME) via drinking water for 5 weeks. Body weight, blood pressure and glucose tolerance, athletic endurance were observed. Cardiac systolic and diastolic function were detected using trans-thoracic Doppler echocardiography. Heart weight/tibial length and wheat germ agglutinin staining (WGA) were performed to evaluate cardiomyocytes. To detect the degree of cardiac fibrosis, picrosirius red (PSR) staining was performed. The coronary microvascular and pericytes were investigated by immunofluorescence staining. Coronary flow reserve (CFR) was measured by echocardiography to assess the coronary microvascular function.
resultsThe HFpEF mouse model was constructed using HFD and L-NAME. HFpEF was evident by preserved ejection fraction (EF), fractional shortening (FS) and significantly elevated E/e’, impaired glucose tolerance and reduced exercise capacity in mice treated with L-NAME and HFD. Cardiomyocyte hypertrophy and cardiac fibrosis were observed in the HFpEF group. The density of capillary was decreased in HFpEF group, accompanied by increased capillary diameter and tortuosity. Moreover, the number and coverage rate of cardiac pericytes were reduced in HFpEF group. No significant differences were found in CFR after modeling 5 weeks. But CFR was decreased in HFpEF group when extending modeling time to 12 weeks.
conclusionsOur findings have demonstrated that coronary microvascular pathological changes appeared during the early stages of HFpEF and appeared before coronary functional indicator changed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.